ℹ️
🇨🇿
Hledání
Hledat osoby relevantní k dotazu "predictability"
predictability
Osoba
Předměty
Osoby
Publikace
Studium
Exportovat aktuální pohled
MUDr. Ester Mejstříková Ph.D.
Akademický pracovník na 2. lékařská fakulta
135 publikací
Publikace
publication
Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia
2013 |
2. lékařská fakulta
publication
Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia
2013 |
2. lékařská fakulta
publication
Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction
2013 |
2. lékařská fakulta
publication
Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis
2011 |
2. lékařská fakulta, 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
publication
Detection of Residual B Precursor Lymphoblastic Leukemia by Uniform Gating Flow Cytometry
2010 |
2. lékařská fakulta
publication
Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia
2024 |
2. lékařská fakulta
publication
Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study
2024 |
2. lékařská fakulta
publication
CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
2024 |
2. lékařská fakulta
publication
The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (vol 36, pg 1720, 2022)
2023 |
2. lékařská fakulta, Lékařská fakulta v Plzni
publication
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study
2022 |
2. lékařská fakulta
Načíst další publikace (125)
Loading network view...